RCMI Coordinating Center (RCMI CC) Header Logo

Connection

Co-Authors

This is a "connection" page, showing publications co-authored by Rajesh Singh and James Lillard.
Connection Strength

5.799
  1. Singh R, Gupta P, Kloecker GH, Singh S, Lillard JW. Expression and clinical significance of CXCR5/CXCL13 in human non-small cell lung carcinoma. Int J Oncol. 2014 Dec; 45(6):2232-40.
    View in: PubMed
    Score: 0.503
  2. Singh R, Gupta P, Sharma PK, Ades EW, Hollingshead SK, Singh S, Lillard JW. Prediction and characterization of helper T-cell epitopes from pneumococcal surface adhesin A. Immunology. 2014 Apr; 141(4):514-30.
    View in: PubMed
    Score: 0.486
  3. Singh R, Singh S, Briles DE, Taub DD, Hollingshead SK, Lillard JW. CCL5-independent helper T lymphocyte responses to immuno-dominant pneumococcal surface protein A epitopes. Vaccine. 2012 Feb 01; 30(6):1181-90.
    View in: PubMed
    Score: 0.414
  4. Singh R, Singh S, Sharma PK, Singh UP, Briles DE, Hollingshead SK, Lillard JW. Helper T cell epitope-mapping reveals MHC-peptide binding affinities that correlate with T helper cell responses to pneumococcal surface protein A. PLoS One. 2010 Feb 25; 5(2):e9432.
    View in: PubMed
    Score: 0.366
  5. Singh R, Lillard JW. Nanoparticle-based targeted drug delivery. Exp Mol Pathol. 2009 Jun; 86(3):215-23.
    View in: PubMed
    Score: 0.338
  6. Singh R, Singh S, Lillard JW. Past, present, and future technologies for oral delivery of therapeutic proteins. J Pharm Sci. 2008 Jul; 97(7):2497-523.
    View in: PubMed
    Score: 0.326
  7. McKinney LP, Singh R, Jordan IK, Varambally S, Dammer EB, Lillard JW. Transcriptome Analysis Identifies Tumor Immune Microenvironment Signaling Networks Supporting Metastatic Castration-Resistant Prostate Cancer. Onco (Basel). 2023 Jun; 3(2):81-95.
    View in: PubMed
    Score: 0.227
  8. Adebayo OO, Dammer EB, Dill CD, Adebayo AO, Oseni SO, Griffen TL, Ohandjo AQ, Yan F, Jain S, Barwick BG, Singh R, Boise LH, Lillard JW. Multivariant Transcriptome Analysis Identifies Modules and Hub Genes Associated with Poor Outcomes in Newly Diagnosed Multiple Myeloma Patients. Cancers (Basel). 2022 Apr 29; 14(9).
    View in: PubMed
    Score: 0.213
  9. Singh SK, Gordetsky JB, Bae S, Acosta EP, Lillard JW, Singh R. Selective Targeting of the Hedgehog Signaling Pathway by PBM Nanoparticles in Docetaxel-Resistant Prostate Cancer. Cells. 2020 08 27; 9(9).
    View in: PubMed
    Score: 0.189
  10. Noel B, Singh SK, Lillard JW, Singh R. Role of natural compounds in preventing and treating breast cancer. Front Biosci (Schol Ed). 2020 03 01; 12(1):137-160.
    View in: PubMed
    Score: 0.183
  11. Singh SK, Lillard JW, Singh R. Reversal of drug resistance by planetary ball milled (PBM) nanoparticle loaded with resveratrol and docetaxel in prostate cancer. Cancer Lett. 2018 07 28; 427:49-62.
    View in: PubMed
    Score: 0.161
  12. Singh SK, Mishra MK, Eltoum IA, Bae S, Lillard JW, Singh R. CCR5/CCL5 axis interaction promotes migratory and invasiveness of pancreatic cancer cells. Sci Rep. 2018 01 22; 8(1):1323.
    View in: PubMed
    Score: 0.158
  13. Singh SK, Singh S, Lillard JW, Singh R. Drug delivery approaches for breast cancer. Int J Nanomedicine. 2017; 12:6205-6218.
    View in: PubMed
    Score: 0.154
  14. Singh SK, Banerjee S, Acosta EP, Lillard JW, Singh R. Resveratrol induces cell cycle arrest and apoptosis with docetaxel in prostate cancer cells via a p53/ p21WAF1/CIP1 and p27KIP1 pathway. Oncotarget. 2017 Mar 07; 8(10):17216-17228.
    View in: PubMed
    Score: 0.149
  15. Banerjee S, Singh SK, Chowdhury I, Lillard JW, Singh R. Combinatorial effect of curcumin with docetaxel modulates apoptotic and cell survival molecules in prostate cancer. Front Biosci (Elite Ed). 2017 03 01; 9(2):235-245.
    View in: PubMed
    Score: 0.149
  16. Singh SK, Lillard JW, Singh R. Molecular basis for prostate cancer racial disparities. Front Biosci (Landmark Ed). 2017 01 01; 22(3):428-450.
    View in: PubMed
    Score: 0.147
  17. Singh R, Kapur N, Mir H, Singh N, Lillard JW, Singh S. CXCR6-CXCL16 axis promotes prostate cancer by mediating cytoskeleton rearrangement via Ezrin activation and av?3 integrin clustering. Oncotarget. 2016 Feb 09; 7(6):7343-53.
    View in: PubMed
    Score: 0.138
  18. El-Haibi CP, Sharma P, Singh R, Gupta P, Taub DD, Singh S, Lillard JW. Differential G protein subunit expression by prostate cancer cells and their interaction with CXCR5. Mol Cancer. 2013 Jun 18; 12:64.
    View in: PubMed
    Score: 0.115
  19. El-Haibi CP, Singh R, Gupta P, Sharma PK, Greenleaf KN, Singh S, Lillard JW. Antibody Microarray Analysis of Signaling Networks Regulated by Cxcl13 and Cxcr5 in Prostate Cancer. J Proteomics Bioinform. 2012; 5(8):177-184.
    View in: PubMed
    Score: 0.104
  20. Singh R, Lillard JW, Singh S. Chemokines: key players in cancer progression and metastasis. Front Biosci (Schol Ed). 2011 06 01; 3(4):1569-82.
    View in: PubMed
    Score: 0.100
  21. Singh R, Stockard CR, Grizzle WE, Lillard JW, Singh S. Expression and histopathological correlation of CCR9 and CCL25 in ovarian cancer. Int J Oncol. 2011 Aug; 39(2):373-81.
    View in: PubMed
    Score: 0.100
  22. Johnson-Holiday C, Singh R, Johnson E, Singh S, Stockard CR, Grizzle WE, Lillard JW. CCL25 mediates migration, invasion and matrix metalloproteinase expression by breast cancer cells in a CCR9-dependent fashion. Int J Oncol. 2011 May; 38(5):1279-85.
    View in: PubMed
    Score: 0.098
  23. Johnson EL, Singh R, Singh S, Johnson-Holiday CM, Grizzle WE, Partridge EE, Lillard JW. CCL25-CCR9 interaction modulates ovarian cancer cell migration, metalloproteinase expression, and invasion. World J Surg Oncol. 2010 Jul 22; 8:62.
    View in: PubMed
    Score: 0.094
  24. El Haibi CP, Sharma PK, Singh R, Johnson PR, Suttles J, Singh S, Lillard JW. PI3Kp110-, Src-, FAK-dependent and DOCK2-independent migration and invasion of CXCL13-stimulated prostate cancer cells. Mol Cancer. 2010 Apr 22; 9:85.
    View in: PubMed
    Score: 0.092
  25. Singh S, Singh R, Singh UP, Rai SN, Novakovic KR, Chung LW, Didier PJ, Grizzle WE, Lillard JW. Clinical and biological significance of CXCR5 expressed by prostate cancer specimens and cell lines. Int J Cancer. 2009 Nov 15; 125(10):2288-95.
    View in: PubMed
    Score: 0.090
  26. Singh S, Singh R, Sharma PK, Singh UP, Rai SN, Chung LW, Cooper CR, Novakovic KR, Grizzle WE, Lillard JW. Serum CXCL13 positively correlates with prostatic disease, prostate-specific antigen and mediates prostate cancer cell invasion, integrin clustering and cell adhesion. Cancer Lett. 2009 Sep 28; 283(1):29-35.
    View in: PubMed
    Score: 0.086
  27. Singh UP, Singh R, Singh S, Karls RK, Quinn FD, Taub DD, Lillard JW. CXCL10+ T cells and NK cells assist in the recruitment and activation of CXCR3+ and CXCL11+ leukocytes during Mycobacteria-enhanced colitis. BMC Immunol. 2008 Jun 04; 9:25.
    View in: PubMed
    Score: 0.081
  28. Singh UP, Singh S, Singh R, Cong Y, Taub DD, Lillard JW. CXCL10-producing mucosal CD4+ T cells, NK cells, and NKT cells are associated with chronic colitis in IL-10(-/-) mice, which can be abrogated by anti-CXCL10 antibody inhibition. J Interferon Cytokine Res. 2008 Jan; 28(1):31-43.
    View in: PubMed
    Score: 0.079
  29. Singh UP, Venkataraman C, Singh R, Lillard JW. CXCR3 axis: role in inflammatory bowel disease and its therapeutic implication. Endocr Metab Immune Disord Drug Targets. 2007 Jun; 7(2):111-23.
    View in: PubMed
    Score: 0.076
  30. Singh UP, Singh S, Singh R, Karls RK, Quinn FD, Potter ME, Lillard JW. Influence of Mycobacterium avium subsp. paratuberculosis on colitis development and specific immune responses during disease. Infect Immun. 2007 Aug; 75(8):3722-8.
    View in: PubMed
    Score: 0.075
  31. Palaniappan R, Singh S, Singh UP, Singh R, Ades EW, Briles DE, Hollingshead SK, Royal W, Sampson JS, Stiles JK, Taub DD, Lillard JW. CCL5 modulates pneumococcal immunity and carriage. J Immunol. 2006 Feb 15; 176(4):2346-56.
    View in: PubMed
    Score: 0.069
  32. VanCleave TT, Moore JH, Benford ML, Brock GN, Kalbfleisch T, Baumgartner RN, Lillard JW, Kittles RA, Kidd LC. Interaction among variant vascular endothelial growth factor (VEGF) and its receptor in relation to prostate cancer risk. Prostate. 2010 Mar 01; 70(4):341-52.
    View in: PubMed
    Score: 0.046
  33. Mir H, Kapur N, Singh R, Sonpavde G, Lillard JW, Singh S. Andrographolide inhibits prostate cancer by targeting cell cycle regulators, CXCR3 and CXCR7 chemokine receptors. Cell Cycle. 2016; 15(6):819-26.
    View in: PubMed
    Score: 0.034
  34. Mir H, Singh R, Kloecker GH, Lillard JW, Singh S. CXCR6 expression in non-small cell lung carcinoma supports metastatic process via modulating metalloproteinases. Oncotarget. 2015 Apr 30; 6(12):9985-98.
    View in: PubMed
    Score: 0.033
  35. Gupta P, Sharma PK, Mir H, Singh R, Singh N, Kloecker GH, Lillard JW, Singh S. CCR9/CCL25 expression in non-small cell lung cancer correlates with aggressive disease and mediates key steps of metastasis. Oncotarget. 2014 Oct 30; 5(20):10170-9.
    View in: PubMed
    Score: 0.032
  36. Moktar A, Singh R, Vadhanam MV, Ravoori S, Lillard JW, Gairola CG, Gupta RC. Cigarette smoke condensate-induced oxidative DNA damage and its removal in human cervical cancer cells. Int J Oncol. 2011 Oct; 39(4):941-7.
    View in: PubMed
    Score: 0.025
  37. Johnson-Holiday C, Singh R, Johnson EL, Grizzle WE, Lillard JW, Singh S. CCR9-CCL25 interactions promote cisplatin resistance in breast cancer cell through Akt activation in a PI3K-dependent and FAK-independent fashion. World J Surg Oncol. 2011 May 03; 9:46.
    View in: PubMed
    Score: 0.025
  38. Johnson EL, Singh R, Johnson-Holiday CM, Grizzle WE, Partridge EE, Lillard JW, Singh S. CCR9 interactions support ovarian cancer cell survival and resistance to cisplatin-induced apoptosis in a PI3K-dependent and FAK-independent fashion. J Ovarian Res. 2010 Jun 17; 3:15.
    View in: PubMed
    Score: 0.023
  39. Zuba-Surma EK, Kucia M, Abdel-Latif A, Dawn B, Hall B, Singh R, Lillard JW, Ratajczak MZ. Morphological characterization of very small embryonic-like stem cells (VSELs) by ImageStream system analysis. J Cell Mol Med. 2008 Jan-Feb; 12(1):292-303.
    View in: PubMed
    Score: 0.020
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
RCMI CC is supported by the National Institute on Minority Health and Health Disparities, National Institutes of Health (NIH), through Grant Number U24MD015970. The contents of this site are solely the responsibility of the authors and do not necessarily represent the official views of the NIH

For technical support please contact support